Voreloxin, a first-in-class anticancer quinolone derivative, in relapsed/refractory solid tumors: a report on two dosing schedules.
Advani RH, Hurwitz HI, Gordon MS, Ebbinghaus SW, Mendelson DS, Wakelee HA, Hoch U, Silverman JA, Havrilla NA, Berman CJ, Fox JA, Allen RS, Adelman DC.
Advani RH, et al. Among authors: berman cj.
Clin Cancer Res. 2010 Apr 1;16(7):2167-75. doi: 10.1158/1078-0432.CCR-09-2236. Epub 2010 Mar 16.
Clin Cancer Res. 2010.
PMID: 20233886
Clinical Trial.